Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:clinical_trial |
Phase 1
Phase 2 Phase 3 |
| gptkbp:focus_area |
oncology
hematology inflammation |
| gptkbp:founded |
gptkb:2002
|
| gptkbp:headquarters |
gptkb:Dublin,_Ireland
|
| https://www.w3.org/2000/01/rdf-schema#label |
Incyte Europe
|
| gptkbp:market |
gptkb:European_Union
gptkb:Iceland gptkb:Norway gptkb:Switzerland gptkb:United_Kingdom |
| gptkbp:number_of_employees |
100-200
|
| gptkbp:parent_company |
gptkb:Incyte_Corporation
|
| gptkbp:partnership |
gptkb:Bristol-Myers_Squibb
gptkb:Merck_&_Co. gptkb:Novartis |
| gptkbp:product |
gptkb:Iclusig
gptkb:Jakafi gptkb:Pemigatinib |
| gptkbp:research_focus |
biologics
small molecules |
| gptkbp:website |
www.incyte.com
|
| gptkbp:bfsParent |
gptkb:Incyte_Biosciences
gptkb:Incyte |
| gptkbp:bfsLayer |
6
|